Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > COLUMN
COLUMN
- AI Is Redefining Healthcare: Insights from Prospection Japan’s Conference
June 27, 2025
- Bridging the Talent Gap: Communication Challenges in Japan’s Pharma & Multinationals
May 30, 2025
- The Evolution of HR: From BP to Agile
April 28, 2025
- Build a Strong Employer Brand - What Can You Do If Your Company Stinks?
March 19, 2025
- 4 Things Your Firm Can Do to Attract and Retain Top Talent in Japan’s Pharmaceutical and Medical Device Industry
February 14, 2025
- A Conversation with Bill Schuster: Navigating the Complexities of Healthcare Leadership
January 24, 2025
- A Conversation with James Feliciano: Navigating the Complexities of the Japanese Pharmaceutical Industry
December 23, 2024
- How to Be a Country Manager
November 29, 2024
- Elevating Leadership: Insights from Japan’s Healthcare Sector
October 23, 2024
- 6 Tips for Motivating and Engaging Current Employees
September 30, 2024
- Why LinkedIn Isn’t Effective in Japan
August 27, 2024
- The Dynamics of Field Medical Visits: Importance of Balancing Quality and Frequency in Medical Interactions
August 2, 2024
- 3 Common Mistakes Made when Hiring a Leader
July 25, 2024
- 3 Tips for Establishing Local Connections in Japan
June 28, 2024
- How to Plan for Future Talent Needs
May 31, 2024
- Boosting Employee Retention in a Competitive Market
April 18, 2024
- How to Paint an Irresistible Picture of Success
March 22, 2024
- Positioning Your Company as an Employer of Choice
February 22, 2024
- Navigating the Evolving Landscape of Medical Affairs: Integrating Insights and Identity for Future Success
February 7, 2024
- How NOT to Write a Job Description
January 26, 2024
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…